ADHD, Gender, and the SLC6A2 gene

We are currently plowing through the four candidate ADHD genes listed below which have been investigated for gender dependence based on an article by Biederman and coworkers. The four genes are:

• SLC6A4 Gene
  
• COMT Gene
• SLC6A2 Gene
• MAOA Gene

We have seen in previous posts that both the COMT gene, and to a lesser extent, the SLC6A4 gene have exhibited a gender dependent behavior with regards to the disorder of ADHD. In other words, certain forms of these genes tend to turn up at a higher frequency in males with ADHD than in females with ADHD. While both SLC6A4 (which is often referred to as a Serotonin Transporter Gene or SERT), and the COMT (short Catechol Methyltransferase, an important enzyme of relevance to ADHD and related disorders) gene effects on ADHD are suggestively greater in boys, the SLC6A2 and MAOA genes are believed to have a greater impact on ADHD in girls. We will be investigating the SLC6A2 gene here:

Location of the SLC6A2 gene:
SLC6A2 is a gene located on the 16th human chromosome. It is responsible for coding the important protein Norepinephrine Transporter Protein 1, and hence, the gene (as well as the protein that it codes for) frequently go by the abbreviation NET.

Clinical relevance of this SLC6A2 gene:
Norepinephrine is an important signaling agent in the nervous system, and deficiencies of this important chemical are often seen in various brain regions of individuals with ADHD. The protein is analogous to other proteins we've previously discussed, such as the Serotonin Transporter Protein, which is often abbreviated as SERT (which is coded by the SLC6A4 gene which was previously mentioned), and the the Dopamine Transporter Protein (DAT), which we've discussed in other previous posts. The NET, SERT, and DAT proteins are responsible for clearing Norepinephrine, Serotonin and Dopamine from the areas in between nerve cells and into the surrounding cells themselves, which aims at establishing an optimal balance of these three signaling chemicals in and out of the cells.

This is especially important and clinically relevant to ADHD, where the signaling chemicals (especially Norepinephrine and Dopamine) are often out of balance, often exhibiting a sub-optimal concentration of these signaling agents on the outside of the cells. Many stimulants and other ADHD medications work by correcting this imbalance by targeting these protein transporters which shuttle the signaling chemicals in and out of the cells and surrounding areas.

However, different gene forms can actually affect the activity of these shuttling transporters as well, which can disrupt the balance of these important neuro-signaling chemicals Norepinephrine, Dopamine, and Serotonin. As a result, different forms of the genes that code for these transporter proteins may actually play a role of how great the imbalance of these signaling chemicals is, which can affect how much of a particular medication is actually needed to correct these imbalances. In other words, the amount of stimulant medication one may need for ADHD may ride, at least in part, on which form of COMT, NET and DAT genes that particular person has. For a more visual and detailed look at this gene-medication relationship, please see this earlier blog post on titled ADHD genes influence medication dosage.

Other disorders associated with the SLC6A2 gene:
Anorexia:
There is widespread discussion as to the overall prevalence of eating disorders in individuals with ADHD compared to the general population. However, several studies have linked ADHD to significantly higher rates of eating disorders. If this holds true for the population, another study of potential interest may involve the SLC6A2 gene. A particular form of this gene (referred to by the alternate term norepinephrine transporter gene in the paper) was associated with doubling the risk of developing anorexia nervosa.

Orthostatic Intolerance:
Orthostatic intolerance is a disorder in which noticeable physiological differences (heart rate, lightheadedness, fainting, etc.) occur as a result of postural changes (i.e. going from laying down or sitting to standing). Of course, some of these signs occasionally affect everyone, but for some individuals, the differences are much more pronounced and much more severe.

According to a study done by Shannon and coworkers, it is believed that the SLC6A2 gene (again, called norepinephrine transporter in this paper) may play a role in the effects of orthostatic intolerance. A mutant form of this norepinephrine transporter gene resulted in around a 50-fold reduction in functional ability of the norepinephrine transporter protein coded for by this mutant form of the SLC6A2 gene and was susceptible to major changes in norephinephrine levels and pronounced physiological changes upon changing postural positions (to the standing position). As a result, a fully functional SLC6A2 gene is apparently critical in regulating stable physiological functions in individuals.


Male vs. Female Differences of SLC6A2 and ADHD:
Like the SLC6A4 gene (and unlike the COMT gene) mentioned previously, the SLC6A2 gene showed statistically significant gender-based differences in preliminary tests, but failed to reach statistical significance upon a more detailed analysis. However, the authors of the study were quick to point out that there were gender-based differences in a specific sub region of this gene. Nevertheless, we must keep in mind that this gene, should it actually influence gender-based differences in ADHD patients, would play a much more minor role in the process than would other genes such as the previously-discussed COMT gene and the soon-to-be discussed MAOA gene.

As a note of potential interest, animal studies have actually shown differences based on analogous forms of this gene. For example, a study on rats (which, in general, shows a surprisingly high degree of overlap with human psychological disorders), showed that there was a gender-different responses to stress, even after gender-based hormonal differences had been taken into account. In addition, another analogous rat-based anxiety study (note that we previously discussed how females with ADHD exhibit more comorbid anxiety disorders than do ADHD males) showed that female rats without the SLC6A2 gene were much more prone to exhibiting behaviors of fear and anxiety than were male rats without the gene.

This possibly suggests a greater gender dependence of this gene, that is a greater "need" for a fully functioning SLC6A2 gene in females than in males. This may have potential implications in ADHD individuals, (many of whom exhibit some sort of anxiety-related disorder alongside their ADHD) by demonstrating a gender-based genetic influence into the mix. In this blogger's opinion, it is possible that genetic and clinical screenings for the SLC6A2 gene may be potentially useful factors in predicting one's likelihood of developing ADHD with a co-occurring anxiety disorder in the near future.

In the next post, we will finish our discussion of the four gender-based ADHD genes by going over the last gene of the series, the MAOA gene.

The ADHD and Bulimia Connection

ADHD is a disorder that has numerous comorbids ("comorbids" refer to disorders that often accompany or are seen alongside of ADHD). These include, but are not limited to: Depression, Tourette's, Conduct Disorders, Sleep Disturbances, Restless Legs Syndrome, Body mass and obesity issues, dysgraphia (poor writing skills and abilities), processing disorders, sensory integration disorders as well as several others.

In the midst of all of these co-occurring disorders, there are a few that often evade the attention of both researchers and the general public. One of these is the disorder bulimia nervosa. Bulimia nervosa (which is often simply referred to as bulimia), which is often characterized by eating (and often binging) followed by purging, is a major issue in many industrialized nations, especially among teens and young women. Based on a study by Surman and co-workers, it appears that there is a relatively high correlation and prevalence of bulima and ADHD. A link to a quick synopsis of the study can be found here, but for sake of time, I will summarize a few key findings from the article:

• Impulsive behavior is a hallmark characteristic of ADHD, and impulsivity is also thought to be a major factor in bulimia as well. It is even hypothesized that some type of underlying factor may be responsible for governing both disorders.

• Given the fact that the disorder of bulimia is expressed at much higher frequencies in young females in late adolescence and early adulthood, it is interesting to note that correlations between the two disorders were relatively weak for men and non-adult women. Additionally, this is worth mentioning because the percentage of individuals with ADHD is heavily skewed towards the male side. That being said, the fact that there was not more of a correlation between ADHD and bulimia in males could be a reflection of either a poor sample size or representation of t he general population, or a relatively weak connection between the two disorders (i.e., one this is unable to override the so-called gender bias of bulimia favoring women and ADHD favoring men).

• These results were tallied from 4 relatively large sample pools previously constructed to evaluate the effects of ADHD over an extended, longitudinal, multi-year period of time. This suggests that some of these relatively strong bulimia/ADHD correlations did not appear simply due to random statistical chance.

• Like ADHD, bulimia has been tied to functional imbalances involving several systems of neurotransmitters, which include serotonin and norepinephrine. It is also possible that hormonal surges during puberty may increase imbalances of neurotransmitters like serotonin, especially in females. Since serotonin levels are tied to feelings of satiation or fullness, imbalanced in this key neurotransmitter can interfere with the feedback of normal eating patterns. In addition to social and environmental pressures, this neurotransmitter imbalance may be another contributing factor to the prevalence of bulimia, anorexia and other eating disorders in females of this age.

• Stimulant medications, such as methylphenidate, which are often the first line of treatment for individuals with ADHD, especially those showing pronounced signs of impulsivity and hyperactivity, have shown potential in the treatment of bulimia, albeit through studies with very small sample sizes.

Taking this one step further, it appears that genetics may be an additional overlapping factor involved in stimulant medication treatment for ADHD. For example, some research suggests that different forms of DAT1 may be responsible for the effects of methylphenidate on appetite and eating behaviors including purging (DAT is short for "Dopamine Transporter Gene"). We have seen previously that there is a connection between the DAT gene and ADHD. Located on human chromosome #5, DAT1 has been linked to Parkinson's, Tourette's and substance abuse.

Additionally, proteins coded for by the DAT gene are expressed in high concentrations in the basal ganglia region of the brain. The basal ganglia is essentially responsible, among other things, for determining how fast a person's brain "idles" For example, "type A" individuals, who are often workaholics, easily stressed, and always on the go at 100 miles per hour often have overactive basal ganglia, while the more relaxed, easy-going, "type B" personalities typically have less activity in this critical brain region. While there also appears to be a significant overlap between bulimia and depression, individuals with bulimia typically display higher basal ganglia activities than those with isolated depressive symptoms.

Given the prevalent distribution of this gene's expressed proteins in key brain regions like the basal ganglia, and the role of involvement of these brain regions in eating disorders, the DAT gene may be an important determining and regulating factor for bulimia and other eating disorders, especially in the context of comorbid ADHD.

Please note: These final remarks are simply this blogger's opinion on the subject:
I personally find this connection between ADHD and bulimia to be interesting. However, I do believe that we should be cautious when investigating ADHD comorbid disorders. It is tempting sometimes to fall into the trap of falsely assuming that correlation always implies causation, and trying to find underlying causes for disorders and attempting to link ADHD to every other disorder under the sun.

However, the role of the DAT genes, which have been tied to ADHD, do offer at least some credence to at least some degree of genetic predisposition to both ADHD and bulimia. This claim is further strengthened by the degree of overlap involving medication treatments of the two disorders, namely stimulants. However, there have been several documented cases of the disappearance of bulimia symptoms following treatment with methylphenidate (Ritalin, Concerta, Daytrana, etc.) for comorbid ADHD.

As a result, we may be faced with a "chicken and egg" question: "Does bulimia increase the risk of ADHD or does ADHD increase the risk of bulimia?" (or even "Are they both side effects of an even larger underlying cause?"). Another plausible explanation is that ADHD is a culmination of secondary effects involving bulimia and other eating disorders. Constant purging will typically wreak havoc on the digestive system and lead to improper food and nutrient absorption. I have hinted in previous posts that digestive disorders such as celiac disease can often manifest symptoms which closely approximate those of ADHD. Given the mounting evidence connecting ADHD (or other disorders which exhibit closely related symptoms which could potentially lead to a "false" diagnosis of ADHD if one is not careful) to nutrient deficiencies, it is quite possible that ADHD and its symptoms are secondary effects of nutritional deficits caused by eating disorders such as bulimia.